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Abstract
Chronic kidney disease (CKD) is an important public health problem in American Indian populations.
Recent research has identified associations of polymorphisms in the myosin heavy chain type II
isoform A (MYH9) gene with hypertensive CKD in African-Americans. Whether these associations
are also present among American Indian individuals is unknown. To evaluate the role of genetic
polymorphisms in the MYH9 gene on kidney disease in American Indians, we genotyped 25 SNPs
in the MYH9 gene region in 1,119 comparatively unrelated individuals. Four SNPs failed, and one
SNP was monomorphic. We inferred haplotypes using seven SNPs within the region of the previously
described E haplotype using Phase v2.1. We studied the association between 20 MYH9 SNPs with
kidney function (estimated glomerular filtration rate, eGFR) and CKD (eGFR < 60 ml/min/1.73
m2 or renal replacement therapy or kidney transplant) using age-, sex- and center-adjusted models
and measured genotyped within the variance component models. MYH9 SNPs were not significantly
associated with kidney traits in additive or recessive genetic adjusted models. MYH9 haplotypes were
also not significantly associated with kidney outcomes. In conclusion, common variants in MYH9
polymorphisms may not confer an increased risk of CKD in American Indian populations.
Identification of the actual functional genetic variation responsible for the associations seen in
African-Americans will likely help to clarify the lack of replication of this gene in our population of
American Indians.
Introduction
Chronic kidney disease (CKD) is highly prevalent in American Indians and contributes to
increased burden of disease in this population (Narva 2003). Among American Indian and
Alaskan Native participants in the Kidney Early Evaluation Program (2000–2006), 29% had
either reduced kidney function or microalbuminuria (Jolly et al. 2009). In the Strong Heart
Study (SHS), increased urine albumin excretion was observed in 20–48% of the American
Indian participants (Robbins et al. 1996), and it was associated with older age, type 2 diabetes
(which is highly prevalent at ~53%), hypertension and percentage of Indian blood. American
Indians have twice the risk of end-stage renal disease (ESRD) compared to individuals of
European ancestry (2009; Scavini et al. 2007) with a younger median age of incident ESRD
(57.6 years) than African-American individuals (58.9 years) and Whites (67.1 years) (2009).
Recent research has linked genetic variation in the myosin heavy chain type II isoform A
(MYH9) gene to hypertensive ESRD and focal segmental glomerulosclerosis (FSGS), the most
common glomerulonephritis associated with ESRD (Kao et al. 2008; Kopp et al. 2008). These
studies used admixture models, which rely on alleles that differ in frequency across populations
of different ancestry and are suitable to the study of diseases, such as CKD, with large
disparities among racial/ethnic groups. Among individuals primarily of African descent,
several single nucleotide polymorphisms (SNPs) in the MYH9 gene were associated with FSGS
(odds ratio, OR = 5.0, 95% confidence interval, CI = 3.5–7.1 for haplotype E-1) and with non-
diabetic ESRD (OR = 2.2, 95% CI = 1.5–3.4) (Kopp et al. 2008). These findings have been
replicated in a large sample of African-Americans with ESRD attributed to hypertension
(Freedman et al. 2009b) and for albuminuria in African-American participants of the
HyperGEN study (Freedman et al. 2009c). The at risk MYH9 haplotype E-1 (comprising three
SNPs in intron 23 and rs3752462) is less often observed in individuals of European descent
(Kopp et al. 2008). Whether the MYH9 gene is also associated with CKD among American
Indian individuals is unknown.
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In this study, we genotyped multiple SNPs in the MYH9 gene and studied the association of
these genetic variants with kidney function (eGFR) and albuminuria in a large sample of
American Indian participants of the Strong Heart Family Study.
Methods
Population and phenotypes
The National Heart, Lung, and Blood Institute (NHLBI) funded the Strong Heart Family Study
(SHFS) beginning in 1998 to study the genetics of cardiovascular disease among American
Indian populations (North et al. 2003). The SHFS recruited members of 94 large,
multigenerational families (mean family size 40 individuals, range 5–110) from the original
cohort of participants of the Strong Heart Study. Over 3,800 American Indians aged 14–93
years from 13 tribes located in Arizona, North and South Dakota, and Oklahoma were
examined. The SHFS protocols were approved by the Indian Health Service Institutional
Review Board, by the Institutional Review Boards of the participating Institutions, and by the
Indian tribes participating in these studies (Lee et al. 1990; North et al. 2003). All participants
gave informed consent for genetic testing. For this study, a sample of comparatively unrelated
individuals [with 753 half-sib relative pairs (kinship coefficients of 0.25) and 2,891 of first
cousin relationship or less (kinship coefficients ≤0.125) among them] were genotyped (N =
1,119).
Socio-demographic data and medical history were obtained by a personal interview during a
clinical exam. Self-reported Indian heritage was obtained by asking the percentage of Indian
blood. Forearm resting blood pressure was measured three consecutive times by a trained
person using a mercury column sphygmomanometer (WA Baum Co) and size-specific cuffs
after 5 min of resting. The first and fifth Korotkoff sounds were recorded. The average of the
last two measures was used for all analyses. Hypertension was defined by a systolic BP ≥140
or diastolic BP ≥90 or use of antihypertensive drugs (Chobanian et al. 2003). Anthropometric
measures of body weight (kg) and height (m) were used to estimate body mass index (BMI,
kg/m2). Type 2 diabetes was defined as a fasting blood glucose of 126 mg/dl or higher, history
of diabetes or use of diabetic medications (1997). Impaired glucose-tolerance was defined by
the World Health Organization criteria and was based on fasting plasma glucose and 75-g oral
glucose-tolerance test results.
Albumin and creatinine were measured in a random urine sample using nephelometric
immunochemistry and alkaline picrate methods, respectively. Urinary albumin excretion was
estimated by the albumin to creatinine ratio (ACR, mg/g). Serum creatinine was measured in
fasting samples by the picric acid method in the MedStar Research Institute (Washington, DC).
Glomerular filtration rate (eGFR) was estimated using the abbreviated Modification in Diet in
Renal Diseases (MDRD) equation: eGFR (ml/min/1.73 m2) = 186.3 × (serum
creatinine)−1.154 × (age)−0.203 × (0.742 if female) × (1.210 if African-American) (Levey et al.
1999). This equation has been previously validated in an American Indian population (Perkins
et al. 2005). eGFR values higher than 200 were set to 200 ml/min per 1.73 m2 (N = 2) and those
less than 15 ml/min per 1.73 m2 were set to 15 (N = 17). CKD was defined by an eGFR of 60
ml/min/1.73 m2 or lower, a history of dialysis or kidney transplant. Urine ACR categories were
defined by <30 mg/g versus ≥30 mg/g urine creatinine.
Genotyping
Twenty-five SNPs were selected in the MYH9 region based on polymorphisms in HapMap
Asian and Caucasian (CEU) populations and if they were available in the Illumina platform.
We used this strategy for two primary reasons. First, there is a paucity of published data on
SNP and haplotype variation in American Indians, specifically for this gene. Second, while we
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could have chosen to select tag SNPs using the Caucasian or Asian HapMap samples, a recent
study using HapMap data to capture patterns of variation in populations not represented in the
HapMap (Conrad et al. 2006) demonstrated that American Indian population, represented by
the Pima Indians, had only 60–70% tag portability with HapMap Han Chinese and Japanese
combined samples. However, the portability of these samples to American Indians represented
in our study is unknown. The SNPs were genotyped in 1,119 individuals by inclusion in an
Illumina iSelect Custom 12-Sample BeadChip using the Infinium II Assay. The assays were
performed according to the manufacturer’s protocol (Illumina, San Diego, CA, USA), and
alleles were detected and analyzed using the Illumina BeadArray Reader and Bead-Studio
software. Replica samples were included as controls. Four SNPs failed the assay (rs136187,
rs9610489, rs2413398, and rs1557540) and one SNP was monomorphic (rs735854). All
remaining SNPs had a call rate >95%.
Haplotypes
Of four SNPs that have defined the E haplotype (at risk haplotype) in African-Americans
(rs4821480, rs2032487, rs4821481, and rs3752462), only one SNP had a minor allele
frequency (MAF) >5% in HapMap Asian samples (rs3752462, MAF = 0.43) and was
genotyped in the SHFS (see also supplemental material). We then selected seven SNPs located
within the haplotype E region for haplotype analyses (chromosome 22, position 35,019,747–
35,034,683 bp). Haplotypes were inferred using Phase (version 2.1), which implements a
Bayesian statistical method for reconstructing haplotypes from population genotype data
(Stephens et al. 2001).
Statistical analysis
Quantitative traits with non-normal distribution were log-transformed for analysis. We tested
the association of SNPs (and haplotypes) of the MYH9 gene with kidney traits using measured
genotyped within the variance component models (Boerwinkle et al. 1986). Models were
adjusted for the random effects of relatedness among individuals and fixed effects of age, sex,
center and degree of Indian blood (as an estimate of ancestry). We also tested for population
stratification using the quantitative transmission disequilibrium test in SOLAR (Havill et al.
2005). We used additive genetic models, but we also performed analyses using recessive
models as these models were used in published studies in African-Americans (Kao et al.
2008; Kopp et al. 2008). In additional analysis, we excluded individuals with diabetes since
the association has been described for non-diabetic CKD (N = 59 CKD). All analyses were
performed in SOLAR using variance component models. For haplotype analyses, we used the
number of copies of the haplotype. Unadjusted P values were reported. We used Bonferoni
methods to correct for multiple testing and considered an alpha of 0.0025 (0.05/20 SNPs) for
significant findings. Three individuals with a kidney transplant were removed from the analysis
of GFR and albuminuria but contributed data for the CKD analyses.
Results
Of the 1,119 genotyped individuals, 64% were women, 48% had hypertension, 37% had type
2 diabetes, and an additional 9% had impaired fasting glucose (Table 1). The mean eGFR was
90.3 ml/min/1.73 m2, and the median urinary albumin to creatinine ratio was 10.7 mg/g. Twelve
percent of individuals (n = 139) had CKD, and 32% (n = 353) had reduced kidney function
and/or increased albuminuria. One of 1,119 individuals was excluded due to low genotyping
(missing rate >0.05). All SNPs were in Hardy–Weinberg equilibrium except for rs2239784
(Table 2).
Figure 1 shows the linkage disequilibrium (LD) of the 20 genotyped SNPs that passed quality
control. SNPs previously shown to be associated with kidney outcomes in African-Americans
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are shown in bold in Tables 2 and 3. Using additive or recessive genetic models, we did not
find significant associations among the MYH9 SNPs and kidney traits in age-, sex- and center-
adjusted models and in models adjusted for population stratification using percentage of Indian
blood (Tables 2, 3; test for stratification was also not significant). In addition, the eGFR and
ACR findings were not significant in analysis excluding individuals with type 2 diabetes (data
not shown).
Three common haplotypes were identified within the selected gene region (Fig. 2). Inferred
haplotypes were also not associated with kidney outcomes (Fig. 2).
Discussion
The MYH9 gene has been recently identified for genetic susceptibility of CKD in African-
American individuals with ESRD, FSGS, and albuminuria (Freedman et al. 2009a, b; Kao et
al. 2008; Kopp et al. 2008). Our study of American Indians was unable to replicate the
association of this gene with CKD defined by either reduced kidney function or albuminuria.
American Indians have a high prevalence of type 2 diabetes, obesity, and smoking, all risk
factors for CKD. Although the prevalence of diabetes is high among American Indians, a large
number of non-diabetic individuals have increased albuminuria (Robbins et al. 1996),
suggesting that the causal mechanisms for kidney disease may be independent of diabetes.
Albuminuria is highly associated with Indian blood quantum in this population (Robbins et al.
1996) suggesting a strong genetic susceptibility to CKD.
Although the rates of diabetic ESRD among American Indians have recently declined (27.7%
since 1995), ESRD among diabetic individuals still accounts for most of the cases in the US
in 2006 (329 per million population for a total incidence of 489 per million) (2006). MYH9
genetic susceptibility has been described mostly for non-diabetic CKD. Therefore, it is possible
that this gene is not an important genetic risk factor for CKD in American Indian populations
if most of the CKD cases are due to diabetes. However, a recent study of African-Americans
has shown significant association of MYH9 with diabetic ESRD (Freedman et al. 2009a)
suggesting a broad genetic risk effect across kidney diseases. Alternatively, it is possible that
individuals with diabetes and ESRD may have underlying kidney disease unrelated to diabetes
(Mazzucco et al. 2002). In our population of American Indians, kidney biopsy is not available,
and, therefore, we cannot exclude the possibility that other causes of kidney disease are present
in individuals with type 2 diabetes.
The lack of replication of these gene polymorphisms in American Indians is intriguing, and
may be due to differences in LD structure in this population as compared to African-Americans
and Caucasians. Although we were unable to reconstruct the at risk haplotype (E) for CKD,
four of the genotyped SNPs in our study have been previously shown to be independently
associated with CKD in African-Americans (SNPs in bold in Tables 2, 3). In addition,
haplotype analyses using seven SNPs located within the haplotype E region were not
significantly associated with kidney outcomes (Fig. 2). Given the effect size of these
associations in prior published studies and the MAF for some of the SNPs (varying from 0.05
to 0.49), it is unlikely that our findings are due to low power (see supplemental material for
power analyses). It is possible that the contribution of the gene for CKD risk is obscured by
differences in environmental exposures in this population and gene–environment interactions.
An alternative explanation is that haplotypes conferring risk in African-Americans and
haplotypes conferring a protective effect in individuals of European ancestry are less common
in American Indians. Identification of the actual functional genetic variation responsible for
the associations seen in African-Americans will likely help to clarify the lack of replication of
this gene in American Indians.
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Linkage disequilibrium of genotyped SNPs of the MYH9 gene. SNPs are displayed in the left
column ordered by position in base-pair. Right column shows the correlation among SNPs
based on r2
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Location of the SNPs genotyped within the MYH9 gene and flanking regions using NCBI Build
36.1(a). The figure also shows previously published SNPs genotyped in African-Americans
(Published SNPs). Position of SNPs used to infer haplotypes (Phase v2.1) in the chromosome
22 region between 35019747 and 350334683 bp (b). The three most common haplotypes are
displayed (SNP order: rs5756129, rs5756130, rs9619601, rs2239781, rs2157256, rs3830104,
and rs3752462). P values for association of haplotype copies and kidney outcomes are also
displayed. ACR albumin to creatinine ratio; eGFR estimated glomerular filtration rate; CKD
chronic kidney disease
Franceschini et al. Page 9

























Franceschini et al. Page 10
Table 1
Characteristics of American Indians genotyped for MYH9 SNPs on chromosome 22
Characteristics of the sample (N = 1,119)
Age (years), mean (SD) 53.2 (14.7)
Female sex, N (%) 716 (64)
SBP, mean (SD) 127.7 (18.2)
DBP, mean (SD) 76.5 (11.0)
Hypertension, N (%) 542 (48)
Hypertension treatment, N (%) 415 (37)
Type 2 diabetes, N (%) 409 (36.6)
IFG, N (%) 99 (8.9)
Current smoking, N (%) 338 (30)
eGFR, mean (SD) 90.3 (29.3)
UACR, median (interquartiles) 10.7 (6.1, 31.3)
CKD, N (%) 139 (12)
Microalbuminuria, N (%) 201 (18.2)
Macroalbuminuria, N (%) 82 (7.4)
SD standard deviation; N number; SBP systolic blood pressure; DBP diastolic blood pressure; IFG impaired fasting glucose; UACR urine albumin to
creatinine ratio; eGFR estimated glomerular filtration rate; CKD chronic kidney disease, defined by a eGFR <60 or dialysis or kidney transplantation
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